G. Flesch, Overview of the Clinical Pharmacokinetics of Oxcarbazepine, Clinical Drug Investigation, vol.42, issue.12, pp.185-203, 2004.
DOI : 10.2165/00044011-200424040-00001

A. Volosov, S. Xiaodong, E. Perucca, B. Yagen, A. Sintov et al., Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects, Clinical Pharmacology & Therapeutics, vol.66, issue.6, pp.547-53, 1999.
DOI : 10.1053/cp.1999.v66.103170001

G. Flesch, C. Czendlik, R. D. Lloyd, and P. , Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine, Drug Metabolism and Disposition, vol.39, issue.6, pp.1103-1113, 2011.
DOI : 10.1124/dmd.109.030593

D. Kim, N. Gu, I. Jang, K. Chu, K. Yu et al., Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy, Epilepsia, vol.58, issue.Suppl. 4, pp.9-12, 2012.
DOI : 10.1111/j.1365-2125.2004.02129.x

T. May, E. Korn-merker, and B. Rambeck, Clinical Pharmacokinetics of Oxcarbazepine, Clinical Pharmacokinetics, vol.16, issue.7, pp.1023-1065, 2003.
DOI : 10.2165/00003088-200342120-00002

P. Patsalos, D. Berry, B. Bourgeois, J. Cloyd, T. Glauser et al., Antiepileptic drugs -best practice guidelines for therapeutic drug monitoring : A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, vol.49, issue.7, pp.1239-76, 2008.

S. Striano, P. Striano, D. Nocera, P. Italiano, D. Fasiello et al., Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy, Epilepsy Research, vol.69, issue.2, pp.170-176, 2006.
DOI : 10.1016/j.eplepsyres.2006.01.011

P. Borusiak, E. Korn-merker, N. Holert, and H. Boenigk, Oxcarbazepine in treatment of childhood epilepsy: A survey of 46 children and adolescents, Journal of Epilepsy, vol.11, issue.6, pp.355-60, 1998.
DOI : 10.1016/S0896-6974(98)00041-3

P. Bring and M. Ensom, Does Oxcarbazepine Warrant Therapeutic Drug Monitoring?, Clinical Pharmacokinetics, vol.34, issue.12, pp.767-78, 2008.
DOI : 10.1038/clpt.1991.158

S. Johannessen and T. Tomson, Pharmacokinetic Variability of Newer Antiepileptic Drugs, Clinical Pharmacokinetics, vol.20, issue.3, pp.1061-75, 2006.
DOI : 10.1111/j.1365-2125.1993.tb00422.x

A. Tartara, C. Galimberti, R. Manni, R. Morini, G. Limido et al., The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid, British Journal of Clinical Pharmacology, vol.31, issue.Suppl. 1, pp.366-374, 1993.
DOI : 10.1111/j.1528-1157.1990.tb05385.x

W. Sallas, S. Milosavljev, D. Souza, J. Hossain, and M. , Pharmacokinetic drug interactions in children taking oxcarbazepine, Clinical Pharmacology & Therapeutics, vol.74, issue.2, pp.138-187, 2003.
DOI : 10.1016/S0009-9236(03)00124-3

I. Sugiyama, T. Bouillon, M. Yamaguchi, H. Suzuki, T. Hirota et al., Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities, Drug Metabolism and Pharmacokinetics, vol.30, issue.2, pp.160-107, 2015.
DOI : 10.1016/j.dmpk.2014.12.002

Y. Wang, H. Zhang, C. Niu, P. Gao, Y. Chen et al., Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy, Acta Pharmacologica Sinica, vol.47, issue.5
DOI : 10.1007/BF00194967

O. Kristensen, N. Klitgaard, B. Jonsson, and S. Sindrup, Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations

P. Lloyd, G. Flesch, and W. Dieterle, Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine, Epilepsia, vol.17, issue.s3, pp.10-13, 1994.
DOI : 10.1097/00007691-199302000-00007

Y. Yu, Q. Zhang, W. Xu, C. Lv, and G. Hao, Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy, Eur J Drug Metab Pharmacokinet, 2015.

J. Peng, H. Zhang, Z. Liu, H. Xu, and Y. Wang, Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy, Int. Journal of Clinical Pharmacology and Therapeutics, vol.52, issue.08, pp.684-92, 2014.
DOI : 10.5414/CP202078

K. Park, J. Kim, E. Joo, D. Seo, S. Hong et al., Drug Interaction and Pharmacokinetic Modeling of Oxcarbazepine in Korean Patients With Epilepsy, Clinical Neuropharmacology, vol.35, issue.1, pp.40-44, 2012.
DOI : 10.1097/WNF.0b013e31824150a5

M. Rouan, M. Decherf, L. Clanche, V. Lecaillon, J. Godbillon et al., Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.658, issue.1, pp.167-72, 1994.
DOI : 10.1016/0378-4347(94)00217-7

A. Samson, M. Lavielle, and F. Mentré, Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-74, 2006.
DOI : 10.1016/j.csda.2006.05.007

URL : https://hal.archives-ouvertes.fr/inserm-00182360

S. Beal, Ways to Fit a PK Model with Some Data Below the Quantification Limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001.
DOI : 10.1023/A:1012299115260

H. Schütz, K. Feldmann, J. Faigle, H. Kriemler, and T. Winkler, C-oxcarbazepine in man, Xenobiotica, vol.22, issue.8, pp.769-78, 1986.
DOI : 10.1007/BF00609629

J. Bertrand, C. Laffont, F. Mentré, M. Chenel, and E. Comets, Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model, The AAPS Journal, vol.13, issue.3, pp.390-404, 2011.
DOI : 10.1208/s12248-011-9282-9

URL : https://hal.archives-ouvertes.fr/inserm-00606915

C. Wang, M. Peeters, K. Allegaert, H. Van-oud-alblas, E. Krekels et al., A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span, Pharmaceutical Research, vol.45, issue.9, pp.1570-81, 2012.
DOI : 10.2165/00003088-200645090-00005

E. Comets, K. Brendel, and F. Mentré, Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R, Computer Methods and Programs in Biomedicine, vol.90, issue.2, pp.154-66, 2008.
DOI : 10.1016/j.cmpb.2007.12.002

URL : https://hal.archives-ouvertes.fr/inserm-00274332

M. Bergstrand, A. Hooker, J. Wallin, and M. Karlsson, Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models, The AAPS Journal, vol.13, issue.2, pp.143-51, 2011.
DOI : 10.1208/s12248-011-9255-z

R. Li, X. Sheng, L. Ma, H. Yao, L. Cai et al., Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy, Therapeutic Drug Monitoring, vol.38, issue.3, pp.365-70, 2016.
DOI : 10.1097/FTD.0000000000000278

M. Samuels and S. Wieteska, Advanced Paediatric Life Support: The Practical Approach, 2011.

C. Southan, J. Sharman, H. Benson, E. Faccenda, A. Pawson et al., The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands, Nucleic Acids Research, vol.44, issue.D1, pp.1054-1055, 2016.
DOI : 10.1093/nar/gkv1037

S. Alexander, W. Catterall, E. Kelly, N. Marrion, J. Peters et al., The concise guide to PHARMACOLOGY, 2015.

H. Cheng and W. Juskot, Pharmacokinetics of reversible metabolic systems, Biopharmaceutics & Drug Disposition, vol.81, issue.9, pp.721-66, 1993.
DOI : 10.1203/00006450-197305000-00004

S. Brar, A. Bhattaram, K. Kumi, H. Zhu, R. Dickinson et al., Available from: http://www.fda.gov First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite, Clinical Pharmacology Review [Internet] Eur J Clin Pharmacol, vol.37, pp.69-74, 1989.

V. Jullien, S. Chhun, E. Rey, O. Dulac, M. Tod et al., Pharmacokinetics of Clobazam and N-Desmethylclobazam in Children with Dravet Syndrome Receiving Concomitant Stiripentol and Valproic Acid, Clinical Pharmacokinetics, vol.8, issue.2, pp.527-563, 2015.
DOI : 10.1186/1750-1172-8-176

D. Iribarnegaray, M. , S. Bueldga, D. , G. Sanchez et al., Carbamazepine Population Pharmacokinetics in Children, Therapeutic Drug Monitoring, vol.19, issue.2, pp.132-141, 1997.
DOI : 10.1097/00007691-199704000-00003

E. Yukawa, S. Higuchi, and T. Aoyama, Phenobarbitone Population Pharmacokinetics from Routine Clinical Data: Role of Patient Characteristics for Estimating Dosing Regimens, Journal of Pharmacy and Pharmacology, vol.23, issue.9, pp.755-60, 1992.
DOI : 10.1007/BF01061382

J. Cloyd, J. Fisher, R. Kriel, and D. Kraus, Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance, Clinical Pharmacology and Therapeutics, vol.53, issue.1, pp.22-31, 1993.
DOI : 10.1038/clpt.1993.5

C. Strassburg, A. Strassburg, S. Kneip, A. Barut, R. Tukey et al., Developmental aspects of human hepatic drug glucuronidation in young children and adults, Gut, vol.50, issue.2
DOI : 10.1136/gut.50.2.259

N. Holford, Y. Heo, and B. Anderson, A Pharmacokinetic Standard for Babies and Adults, Journal of Pharmaceutical Sciences, vol.102, issue.9, pp.2941-52, 2013.
DOI : 10.1002/jps.23574

B. Anderson and N. Holford, Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics, Annual Review of Pharmacology and Toxicology, vol.48, issue.1, pp.303-335, 2008.
DOI : 10.1146/annurev.pharmtox.48.113006.094708

C. Knibbe, Allometric Scaling of Clearance in Paediatric Patients : When Does the Magic of 0.75 Fade ?, Clin Pharmacokinet, vol.56, pp.273-85, 2017.

I. Mahmood, Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings, Clinical Pharmacokinetics, vol.68, issue.2, pp.327-373, 2014.
DOI : 10.2146/ajhp110107

I. Mahmood, Prediction of drug clearance in children from adults: a comparison of several allometric methods, British Journal of Clinical Pharmacology, vol.67, issue.5, pp.545-57, 2006.
DOI : 10.1016/j.taap.2003.10.010

P. Mckee, J. Blacklaw, G. Forrest, R. Gillham, S. Walker et al., A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients., British Journal of Clinical Pharmacology, vol.7, issue.1, pp.27-32, 1994.
DOI : 10.1016/0920-1211(90)90018-Q

J. Armijo, N. Vega-gil, M. Shushtarian, J. Adin, and J. Herranz, 10-Hydroxycarbazepine Serum Concentration-to-Oxcarbazepine Dose Ratio, Therapeutic Drug Monitoring, vol.27, issue.2, pp.199-204, 2005.
DOI : 10.1097/01.ftd.0000155342.93489.fd

C. Souppart, Q. Yin, M. Merz, P. Hu, J. Jiang et al., Bioequivalence of oxcarbazepine oral suspension vs. film-coated tablet in healthy Chinese male subjects, Int. Journal of Clinical Pharmacology and Therapeutics, vol.46, issue.10, pp.538-582, 2008.
DOI : 10.5414/CPP46538

G. Flesch, D. Tudor, J. Denouel, J. Bonner, and R. Camisasca, Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects, Int. Journal of Clinical Pharmacology and Therapeutics, vol.41, issue.07, pp.299-308, 2003.
DOI : 10.5414/CPP41299

. Eiaeds, Enzyme Inducing Anti-Epileptic Drugs; 95CI: non parametric 95% confidence Interval Table 6. Comparison of size-standardized estimates and values reported in the literature